Please Wait...

ICAM 1 // Intercellular Adhesion Molecule 1

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

ICAM-1 is also known as CD54. This adhesion molecule, expressed at the surfaces of immune system and endothelial cells, is up-regulated by cytokine stimulation. ICAM-1 has 5 Ig-like domains, a transmembrane region and a small carboxyl-terminal cytoplasmic domain. ICAM1 bind two integrin: leukocyte function associated antigen (LFA1 and CD11a/CD18) and macrophage 1 antigen (Mac-1, CD11b/CD18) (Bella et al., 1998; Yang et al., 2004).

The extracellular domain of ICAM-1 can be detected in serum of healthy controls and levels are increased under disease. Serum ICAM-1 has been proposed as an indicator of inflammatory disease as soon as 1991 (Rothlein et al., 1991). The mechanism leading to the release of ICAM-1 is not fully understood and there is probably a shedding by membrane protease and an alternative RNA splicing (Witkowska and Borawska, 2004). It is possible that ADAM17 participate in the shedding of ICAM1 (in vitro studies) (Tsakadze et al., 2006).

 

SICAM-1 assay is a solid phase enzyme linked immunoassay which has been validated in the laboratory for measurement in human serum. The kit measures only the wild type allele of ICAM-1 and does not recognize ICAM-1 with the Kilifi mutation.

 

Bella, J., Kolatkar, P.R., Marlor, C.W., Greve, J.M., and Rossmann, M.G. (1998). The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. U. S. A. 95, 4140–4145.

Rothlein, R., Mainolfi, E.A., Czajkowski, M., and Marlin, S.D. (1991). A form of circulating ICAM-1 in human serum. J. Immunol. 147, 3788–3793.

Tsakadze, N.L., Sithu, S.D., Sen, U., English, W.R., Murphy, G., and D’Souza, S.E. (2006). Tumor Necrosis Factor-α-converting Enzyme (TACE/ADAM-17) Mediates the Ectodomain Cleavage of Intercellular Adhesion Molecule-1 (ICAM-1). J. Biol. Chem. 281, 3157–3164.

Yang, Y., Jun, C.-D., Liu, J., Zhang, R., Joachimiak, A., Springer, T.A., and Wang, J. (2004). Structural Basis for Dimerization of ICAM-1 on the Cell Surface. Mol. Cell 14, 269–276.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

On the hunt for agile IRT? Ask these 5 Qs to see if it's the real thing. DISCLOSURE: We happen to have such an offe… https://t.co/S6507WxBC8
bioclinica (6 hours ago)
Be among the 1st to hear findings presented in 6 scientific posters in which experts @bioclinica in #Alzheimers… https://t.co/4mBEtFiX0a
bioclinica (2 days ago)
Still using manual methods for trial budget management and forecasting ? A Bioclinica whitepaper shows how purpose-… https://t.co/WlrHLk9B0z
bioclinica (3 days ago)
Swing by @Bioclinica to discuss global site network partnering opportunities during @MySCRS Asia-Pac Site Solutions… https://t.co/m8GHxSmPMY
bioclinica (4 days ago)
Hello from Clinical Operations in Oncology Trials East Coast where Bioclinica is exhibiting & presenting a case stu… https://t.co/oTKJAVddH4
bioclinica (2 weeks ago)
Challenge overcome! Course-correct a clinical trial & collect 400 time points from 40 sites across the US & EU -- a… https://t.co/n3TLrjW3xi
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen